Hedgehog and Notch signaling regulate self-renewal of undifferentiated pleomorphic sarcomas.

Like many solid tumors, sarcomas are heterogeneous and include a small fraction of the so-called side population (SP) cells with stem-like tumor-initiating potential. Here, we report that SP cells from a soft tissue tumor of enigmatic origin termed undifferentiated pleomorphic sarcoma (also known as malignant fibrous histiocytoma or MFH sarcoma) display activation of both the Hedgehog and Notch pathways. Blockade to these pathways in murine xenograft models, this human cancer decreased the proportion of SP cells present and suppressed tumor self-renewal, as illustrated by the striking inability of xenograft tumors subjected to pathway blockade to be serially transplanted to new hosts. In contrast, conventional chemotherapies increased the proportion of SP cells present in tumor xenografts and did not affect their ability to be serially transplanted. SP cells from these tumors displayed an unexpectedly high proliferation rate which was selectively inhibited by Hedgehog and Notch blockade compared with conventional chemotherapies. Together, our findings deepen the concept that Hedgehog and Notch signaling are fundamental drivers of tumor self-renewal, acting in a small population of tumor-initiating cells present in tumors. Furthermore, our results suggest not only novel treatment strategies for deadly recurrent unresectable forms of this soft tumor subtype, but also potential insights into its etiology which has been historically controversial.

[1]  L. Doyle,et al.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.

[2]  S. Shankar,et al.  Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics , 2012, International journal of cancer.

[3]  G. Heppner,et al.  Mutagenic activity of tumor-associated macrophages in Salmonella typhimurium strains TA98 and TA 100. , 1984, Cancer research.

[4]  G. Heppner Tumor heterogeneity. , 1984, Cancer research.

[5]  C. Huff,et al.  Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma , 2007, Proceedings of the National Academy of Sciences.

[6]  B. Alman,et al.  Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. , 2007, Cancer research.

[7]  B. Thiers,et al.  Identification of cells initiating human melanomas , 2009 .

[8]  A. Krešo,et al.  Cancer Stem Cells and Self-renewal , 2010, Clinical Cancer Research.

[9]  S. Lipkin,et al.  NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. , 2010, Cancer research.

[10]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[11]  M. Kay,et al.  Sarcoma Derived from Cultured Mesenchymal Stem Cells , 2007, Stem cells.

[12]  C. Woodworth,et al.  Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment , 2005, Molecular Cancer Therapeutics.

[13]  J. Verweij,et al.  Effect of ABCG2 genotype on the oral vioavailability of topotecan , 2005, Cancer biology & therapy.

[14]  K. Miyamoto,et al.  Reversal of P-glycoprotein-dependent resistance to vinblastine by newly synthesized bisbenzylisoquinoline alkaloids in mouse leukemia P388 cells. , 2005, Biological & pharmaceutical bulletin.

[15]  C. Dani,et al.  Inhibition of Hedgehog Signaling Decreases Proliferation and Clonogenicity of Human Mesenchymal Stem Cells , 2011, PloS one.

[16]  Chih-Yuan Wang,et al.  In vivo evidence of duality effects for lovastatin in a nude mouse cancer model , 2010, International journal of cancer.

[17]  B. Alman,et al.  Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. , 2006, The American journal of pathology.

[18]  Tatsuya Kobayashi,et al.  Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation , 2008, Nature Medicine.

[19]  S. Bates,et al.  Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. , 2003, Cancer research.

[20]  P. Söderkvist,et al.  mdr-1 Single Nucleotide Polymorphisms in Ovarian Cancer Tissue: G2677T/A Correlates with Response to Paclitaxel Chemotherapy , 2006, Clinical Cancer Research.

[21]  B. Alman,et al.  IFN-{beta} signaling positively regulates tumorigenesis in aggressive fibromatosis, potentially by modulating mesenchymal progenitors. , 2007, Cancer research.

[22]  Mariël Brok,et al.  Imatinib mesylate ( STI 571 ) is a substrate for the breast cancer resistance protein ( BCRP ) / ABCG 2 drug pump , 2004 .

[23]  G. Fleuren,et al.  Tumor Heterogeneity and Immunotherapy of Cancer , 1995, Immunological reviews.

[24]  B. Alman,et al.  Side population cells in human cancers. , 2008, Cancer letters.

[25]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[26]  R. Bhatia,et al.  Stem Cell Quiescence , 2011, Clinical Cancer Research.

[27]  S. Fan,et al.  Significance of CD90+ cancer stem cells in human liver cancer. , 2008, Cancer cell.

[28]  H. Saya,et al.  c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis , 2010, Oncogene.

[29]  S. Steinberg,et al.  Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Patricia A. Dyck,et al.  Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. , 2002, Cancer research.

[31]  Raphael Kopan,et al.  γ-Secretase activity is dispensable for mesenchyme-to-epithelium transition but required for podocyte and proximal tubule formation in developing mouse kidney , 2003, Development.

[32]  J. Gibbs,et al.  Malignant Fibrous Histiocytoma: An Institutional Reviews , 2001, Cancer investigation.

[33]  Mariël Brok,et al.  Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. , 2004, Blood.

[34]  C. Dani,et al.  Activation of Hedgehog Signaling Inhibits Osteoblast Differentiation of Human Mesenchymal Stem Cells , 2009, Stem cells.

[35]  James M. Olson,et al.  Medulloblastoma Growth Inhibition by Hedgehog Pathway Blockade , 2002, Science.

[36]  P. Dirks,et al.  Cancer stem cells in nervous system tumors , 2004, Oncogene.

[37]  S. Bates,et al.  ABCG2: structure, function and role in drug response. , 2008, Expert opinion on drug metabolism & toxicology.

[38]  I. Weissman,et al.  Therapeutic implications of cancer stem cells. , 2004, Current opinion in genetics & development.

[39]  P. Beachy,et al.  Teratogen-mediated inhibition of target tissue response to Shh signaling. , 1998, Science.

[40]  Fei Xing,et al.  Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells , 2011, Oncogene.

[41]  N. Socci,et al.  Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. , 2007, The Journal of clinical investigation.

[42]  Hua Tian,et al.  A paracrine requirement for hedgehog signalling in cancer , 2008, Nature.

[43]  S. Henderson,et al.  Inhibition of γ‐secretases alters both proliferation and differentiation of mesenchymal stem cells , 2007 .

[44]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[45]  G. Laurent,et al.  B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells , 2010, Leukemia.

[46]  Guohui Lin,et al.  Editorial, COCOON 2007 special issue , 2008, Journal of combinatorial optimization.

[47]  S. Angers,et al.  Gli proteins in development and disease. , 2011, Annual review of cell and developmental biology.

[48]  B. Alman,et al.  Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells. , 2010, Cancer research.

[49]  C. Antonescu,et al.  Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M. Nakafuku,et al.  Mouse Suppressor of fused is a negative regulator of Sonic hedgehog signaling and alters the subcellular distribution of Gli1 , 1999, Current Biology.

[51]  H. Itamochi,et al.  Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin. , 2011, Gynecologic oncology.

[52]  S. Henderson,et al.  Inhibition of gamma-secretases alters both proliferation and differentiation of mesenchymal stem cells. , 2007, Cell proliferation.

[53]  A. Moreira,et al.  Benign Mesenchymal Stromal Cells in Human Sarcomas , 2010, Clinical Cancer Research.

[54]  L. Ricci-Vitiani,et al.  Chemotherapy resistance of glioblastoma stem cells , 2006, Cell Death and Differentiation.

[55]  M. Clarke,et al.  Identification of pancreatic cancer stem cells. , 2007, Cancer research.